Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Escitalopram Oxalate Tablets 5mg, 10mg and 20mg (ANDA 090432), which was earlier tentatively approved. The product is ready for launch and has been approved out of Unit III formulations facility in Hyderabad, India
Escitalopram Oxalate Tablets 5mg, 10mg and 20mg are the generic equivalent of Forest Laboratories Inc’s Lexapro Tablets 5mg, 10mg and 20mg is an anti-depressant and falls under the Central Nervous Sytem (CNS) segment. It is indicated for treatment of depression associated with mood disorders and has a market size of approximately $2.8 billion for the twelve months ending March 2012 according to IMS.
Aurobindo now has a total of 158 ANDA approvals (133 Final approvals including 1 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: